- Home
- RADX vs DYAI Comparison
RADX vs DYAI Comparison
Compare RADX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- DYAI
- Stock Information
- Founded
- RADX 2021
- DYAI 1979
- Country
- RADX Australia
- DYAI United States
- Employees
- RADX N/A
- DYAI N/A
- Industry
- RADX
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RADX
- DYAI Health Care
- Exchange
- RADX NYSE
- DYAI Nasdaq
- Market Cap
- RADX 32.5M
- DYAI 28.3M
- IPO Year
- RADX N/A
- DYAI 2004
- Fundamental
- Price
- RADX $4.30
- DYAI $0.98
- Analyst Decision
- RADX Strong Buy
- DYAI Strong Buy
- Analyst Count
- RADX 2
- DYAI 1
- Target Price
- RADX $13.50
- DYAI $6.00
- AVG Volume (30 Days)
- RADX 18.3K
- DYAI 62.0K
- Earning Date
- RADX 02-26-2025
- DYAI 08-12-2025
- Dividend Yield
- RADX N/A
- DYAI N/A
- EPS Growth
- RADX N/A
- DYAI N/A
- EPS
- RADX N/A
- DYAI N/A
- Revenue
- RADX $204,609.00
- DYAI $3,554,344.00
- Revenue This Year
- RADX N/A
- DYAI $22.56
- Revenue Next Year
- RADX N/A
- DYAI $30.95
- P/E Ratio
- RADX N/A
- DYAI N/A
- Revenue Growth
- RADX N/A
- DYAI 57.59
- 52 Week Low
- RADX $3.50
- DYAI $0.91
- 52 Week High
- RADX $50.82
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- DYAI 49.96
- Support Level
- RADX N/A
- DYAI $0.91
- Resistance Level
- RADX N/A
- DYAI $1.02
- Average True Range (ATR)
- RADX 0.00
- DYAI 0.05
- MACD
- RADX 0.00
- DYAI 0.01
- Stochastic Oscillator
- RADX 0.00
- DYAI 46.80
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.